カテゴリ： GlobalData, アメリカ, 企業調査

Retrophin Inc (RTRX)：製薬・医療：M&Aディール及び事業提携情報

◆英語タイトル：Retrophin Inc (RTRX) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード：DATA904C9959
◆発行会社（調査会社）：GlobalData
◆発行日：2018年11月
◆ページ数：79
◆レポート言語：英語
◆レポート形式：PDF
◆納品方法：Eメール
◆対象地域：アメリカ
◆産業分野：製薬・医療
◆販売価格オプション（消費税別）
Single User（1名様閲覧用）USD250 ⇒換算￥37,000見積依頼/購入/質問フォーム
Site License（同一事業所内共有可）USD500 ⇒換算￥74,000見積依頼/購入/質問フォーム
Enterprisewide License（複数事業所内共有可）USD750 ⇒換算￥111,000見積依頼/購入/質問フォーム
※販売価格オプションの説明はこちらで、ご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額（日本円）＋消費税＋配送料（Eメール納品は無料）」です。
※本体価格が￥30,000未満のレポートにつきましては、ハンドリングチャージ￥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日＋5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
※GlobalData社の概要はこちらでご確認いただけます。

このエントリーをはてなブックマークに追加
LINEで送る


【レポートの概要】

Summary
Retrophin Inc (Retrophin) is a biopharmaceutical company that discovers, develops, acquires and commercializes drugs for the treatment of rare diseases. The company’s products include thiola, chenodal and cholbam. It develops drugs for various catastrophic diseases. Retrophin’s pipeline products include sparsentan, used for the treatment of focal segmental glomerulosclerosis; RE-024, a product candidate to treat pantothenate kinase-associated neurodegeneration and RE-034, utilized for the treatment of severe rare diseases. The company markets its products through its distribution partners. It works in partnership with academia and independent researchers to support the development of novel solutions. The company operates in New York and Massachusetts, the US. Retrophin is headquartered in San Diego, California, the US.

Retrophin Inc (RTRX) – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 5
List of Figures 5
Retrophin Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Retrophin Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
Retrophin Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Retrophin Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9
Retrophin Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10
Retrophin Inc, Pharmaceuticals & Healthcare, Deal Details 12
Asset Purchase 12
Retrophin Acquires Liquid Formulation of Ursodeoxycholic Acid from Asklepion Pharma 12
Retrophin Acquires Cholic Acid Rights from Asklepion Pharma 13
Venture Financing 14
Perlstein Lab Raises USD2 Million in Seed Financing 14
Retrophin Raises US$4 Million In Series A Financing 15
Partnerships 16
Retrophin Enters into Agreement with Censa Pharma 16
Retrophin Enters into Research Agreement with National Center for Advancing Translational Sciences and NGLY1 17
Retrophin Enters into Research Agreement with Grace Wilsey Foundation and Warren Family Research Center 18
Retrophin Enters into Agreement with Regents of the University of California 19
Licensing Agreements 20
Retrophin Amends Licensing Agreement with Mission Pharmacal for Thiola 20
Retrophin Enters into Licensing Agreement for Central Nervous System Disorders 21
Retrophin Enters Into Licensing Agreement With Novartis Pharma For Syntocinon Nasal Spray 22
Retrophin Enters Into Licensing Agreement To Develop Product For Autism And Schizophrenia Treatment 23
Ligand Pharma Amends Licensing Agreement with Retrophin 24
Equity Offering 26
Retrophin Raises USD149.4 Million in Public Offering of Shares 26
Retrophin Raises USD40 Million in Public Offering of Shares 27
Retrophin Completes Private Placement Of Shares For US$25 Million 29
Retrophin Announces Private Placement Of Common Stock For US$10 Million 30
Debt Offering 31
Retrophin Raises USD276 Million in Public Offering of 2.5% Notes Due 2025 31
Retrophin Raises USD40 Million in Private Placement of Notes Due 2019 33
Asset Transactions 34
Sanofi Acquires Rights to Pediatric PRV from Retrophin for USD245 Million 34
Turing Pharma Acquires Vecamyl, Syntocinon and ketamine from Retrophin 35
Acquisition 37
Retrophin to Acquire Clinuvel Pharma 37
Retrophin Completes Acquisition Of Manchester Pharma For US$62.5 Million 39
Retrophin Acquires Kyalin Biosciences for USD5 Million 40
Desert Gateway Completes Acquisition Of Retrophin In Reverse Takeover Transaction 41
Retrophin Inc – Key Competitors 42
Retrophin Inc – Key Employees 43
Retrophin Inc – Locations And Subsidiaries 44
Head Office 44
Other Locations & Subsidiaries 44
Recent Developments 46
Financial Announcements 46
Nov 01, 2018: Retrophin reports third quarter 2018 financial results 46
Jul 26, 2018: Retrophin Reports Second Quarter 2018 Financial Results and Announces CEO Transition Plan 49
May 01, 2018: Retrophin Announces First Quarter 2018 Financial Results 52
Feb 27, 2018: Retrophin Reports Fourth Quarter and Full Year 2017 Financial Results 54
Nov 07, 2017: Retrophin Reports Third Quarter 2017 Financial Results 56
Aug 09, 2017: Retrophin Reports Second Quarter 2017 Financial Results 58
May 04, 2017: Retrophin Reports First Quarter 2017 Financial Results 60
Mar 01, 2017: Retrophin Reports Fourth Quarter and Full Year 2016 Financial Results 61
Jan 09, 2017: Retrophin Provides Corporate Update and 2017 Preview 63
Corporate Communications 64
Jul 30, 2018: Retrophin Appoints Noah L. Rosenberg, M.D., as Chief Medical Officer 64
Aug 14, 2017: Retrophin Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) 65
Apr 12, 2017: Retrophin Appoints Ron Squarer to Board of Directors 66
Mar 23, 2017: John A. Orwin Joins Retrophin Board of Directors 67
Feb 13, 2017: Retrophin Appoints William Rote Senior Vice President, Research and Development 68
Legal and Regulatory 69
Aug 17, 2018: Shkreli Lawyer Gets 18-Month Sentence for Ponzi-Like Fraud 69
Aug 04, 2017: Former Hedge Fund Manager Convicted In Multi-Million Dollar Fraud Scheme 70
Clinical Trials 71
Jun 04, 2018: Retrophin Announces Pivotal Phase 3 FORT Study of Fosmetpantotenate in PKAN Opens Enrollment to Pediatric Patients 71
Oct 05, 2017: Retrophin Announces Presentation of New Data from Physician-Initiated Treatment with Fosmetpantotenate at the Child Neurology Society’s 26th Annual Meeting 72
Jul 25, 2017: Retrophin Commences Patient Dosing in International, Registrational Phase 3 Trial of RE-024 in PKAN 74
May 25, 2017: Retrophin Announces Presentations On Late-Stage Clinical Development Program RE-024 at Upcoming Medical Congress 75
May 25, 2017: Retrophin Announces Presentations On Late-Stage Clinical Development Program Sparsentan at Upcoming Medical Congress 76
Mar 01, 2017: Retrophin Provides Sparsentan Regulatory Update 77
Other Significant Developments 78
Jan 08, 2018: Retrophin Provides Corporate Update and 2018 Outlook 78
Appendix 79
Methodology 79
About GlobalData 79
Contact Us 79
Disclaimer 79

List of Tables
Retrophin Inc, Pharmaceuticals & Healthcare, Key Facts, 2017 2
Retrophin Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Retrophin Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
Retrophin Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Retrophin Inc, Deals By Therapy Area, 2012 to YTD 2018 9
Retrophin Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10
Retrophin Acquires Liquid Formulation of Ursodeoxycholic Acid from Asklepion Pharma 12
Retrophin Acquires Cholic Acid Rights from Asklepion Pharma 13
Perlstein Lab Raises USD2 Million in Seed Financing 14
Retrophin Raises US$4 Million In Series A Financing 15
Retrophin Enters into Agreement with Censa Pharma 16
Retrophin Enters into Research Agreement with National Center for Advancing Translational Sciences and NGLY1 17
Retrophin Enters into Research Agreement with Grace Wilsey Foundation and Warren Family Research Center 18
Retrophin Enters into Agreement with Regents of the University of California 19
Retrophin Amends Licensing Agreement with Mission Pharmacal for Thiola 20
Retrophin Enters into Licensing Agreement for Central Nervous System Disorders 21
Retrophin Enters Into Licensing Agreement With Novartis Pharma For Syntocinon Nasal Spray 22
Retrophin Enters Into Licensing Agreement To Develop Product For Autism And Schizophrenia Treatment 23
Ligand Pharma Amends Licensing Agreement with Retrophin 24
Retrophin Raises USD149.4 Million in Public Offering of Shares 26
Retrophin Raises USD40 Million in Public Offering of Shares 27
Retrophin Completes Private Placement Of Shares For US$25 Million 29
Retrophin Announces Private Placement Of Common Stock For US$10 Million 30
Retrophin Raises USD276 Million in Public Offering of 2.5% Notes Due 2025 31
Retrophin Raises USD40 Million in Private Placement of Notes Due 2019 33
Sanofi Acquires Rights to Pediatric PRV from Retrophin for USD245 Million 34
Turing Pharma Acquires Vecamyl, Syntocinon and ketamine from Retrophin 35
Retrophin to Acquire Clinuvel Pharma 37
Retrophin Completes Acquisition Of Manchester Pharma For US$62.5 Million 39
Retrophin Acquires Kyalin Biosciences for USD5 Million 40
Desert Gateway Completes Acquisition Of Retrophin In Reverse Takeover Transaction 41
Retrophin Inc, Key Competitors 42
Retrophin Inc, Key Employees 43
Retrophin Inc, Other Locations 44
Retrophin Inc, Subsidiaries 44

List of Figures
Retrophin Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Retrophin Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Retrophin Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
Retrophin Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Retrophin Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Retrophin Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 7
Retrophin Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Retrophin Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9

★海外企業調査レポート[Retrophin Inc (RTRX)：製薬・医療：M&Aディール及び事業提携情報]についてメールでお問い合わせはこちら
■おすすめ企業レポート■
  • Mitsui Chemicals, Inc.：企業の戦略・SWOT・財務情報
    Mitsui Chemicals, Inc. - Strategy, SWOT and Corporate Finance Report Summary Mitsui Chemicals, Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offer …
  • Funtastic Ltd (FUN)：企業の財務・戦略的SWOT分析
    Funtastic Ltd (FUN) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and t …
  • LG Electronics, Inc.：戦略・SWOT・企業財務分析
    LG Electronics, Inc. - Strategy, SWOT and Corporate Finance Report Summary LG Electronics, Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings …
  • Virgin Media Inc：企業の戦略的SWOT分析
    Virgin Media Inc - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and servi …
  • Kering SA (KER)：企業の財務・戦略的SWOT分析
    Kering SA (KER) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the p …
  • Navistar Defense, LLC：企業の戦略・SWOT・財務情報
    Navistar Defense, LLC - Strategy, SWOT and Corporate Finance Report Summary Navistar Defense, LLC - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerin …
  • Metropolitan Bank and Trust Company：企業の戦略・SWOT・財務分析
    Metropolitan Bank and Trust Company - Strategy, SWOT and Corporate Finance Report Summary Metropolitan Bank and Trust Company - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, …
  • Zocere Inc：製薬・医療：M&Aディール及び事業提携情報
    Summary Zocere Inc (Zocere), formerly Tyrosine Pharmaceuticals Inc is a biotechnology company that develops novel therapeutics for neurological diseases. The company offers services to support the pharmaceutical and biotechnology fields developing stroke-related diagnostics and treatments. Its drugs …
  • Theratechnologies Inc (TH)：製薬・医療：M&Aディール及び事業提携情報
    Summary Theratechnologies Inc (Theratechnologies) is a pharmaceutical company that focuses on the discovery and development of drugs for metabolic disorders. The company develops therapeutic peptide products, with an emphasis on growth releasing factor (GRF) peptides. Its lead products include Egrif …
  • The New York Times Company (NYT)：企業の財務・戦略的SWOT分析
    The New York Times Company (NYT) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and wea …
  • Vertex Pharmaceuticals Incorporated：企業の戦略・SWOT・財務情報
    Vertex Pharmaceuticals Incorporated - Strategy, SWOT and Corporate Finance Report Summary Vertex Pharmaceuticals Incorporated - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, …
  • Zincore Metals Inc：企業の戦略・SWOT・財務分析
    Zincore Metals Inc - Strategy, SWOT and Corporate Finance Report Summary Zincore Metals Inc - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and …
  • American Electric Power Company, Inc.：企業の戦略・SWOT・財務分析
    American Electric Power Company, Inc. - Strategy, SWOT and Corporate Finance Report Summary American Electric Power Company, Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analy …
  • Fujitsu Australia Ltd：企業の戦略的SWOT分析
    Fujitsu Australia Ltd - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and …
  • Anadarko Petroleum Corp Oil & Gas Exploration and Production Operations and Cost Analysis – Q4, 2017
    Anadarko Petroleum Corp Oil & Gas Exploration and Production Operations and Cost Analysis - Q4, 2017 Summary Anadarko Petroleum Corp (Anadarko) is an independent upstream oil and gas company, which carries out exploration, development, production, and marketing of natural gas, crude oil, condensate, …
  • Centogene AG-医療機器分野：企業M&A・提携分析
    Summary Centogene AG (Centogene) is a provider of genetic testing services. The company offers genetic testing for rare hereditary disorders. It offers whole genome sequencing, whole exome sequencing, biomarker and biochemical testing; prenatal testing, DNA extraction and cell culture services. Cent …
  • Naftogaz of Ukraine：企業の戦略的SWOT分析
    Naftogaz of Ukraine - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and se …
  • Slavneft-Yaroslavnefteorgsintez (JNOS)：企業の財務・戦略的SWOT分析
    Summary Slavneft-Yaroslavnefteorgsintez (Slavneft-YANOS), a subsidiary of Slavneft, is an oil and gas company that offers refined petroleum products. The company offers products such as bitumen, motor gasoline, diesel fuel, jet fuel, motor oil, transmission oil, turbine oil, compressor oil, industri …
  • Synedgen Inc：医療機器：M&Aディール及び事業提携情報
    Summary Synedgen Inc (Synedgen) is a biotechnology company that discovers and develops polysaccharide-based drugs, which enhance and mimic the innate immune system. The company’s pipeline products include SYGN305, SYGN399, SYGN303, SYGN313 and SYGN309. Synedgen develops products for the treatment of …
  • The Empire District Electric Company-エネルギー分野：企業M&A・提携分析
    Summary The Empire District Electric Company (EDE), a subsidiary of Liberty Utilities Co., is a regulated utility that provides electricity, natural gas, and water services. The company generates, procures, transmits, distributes, and sells electricity. It generates electricity from natural gas, coa …

◆H&Iグローバルリサーチ株式会社のお客様（例）◆